First- and second-generation antipsychotics

Canadian Journal of Psychiatry

Volumn 55, Issue 3, 2010, Pages 144-149

  McEvoy, Joseph P ^a   Zigman, Daniel ^b   Margolese, Howard C ^b,c,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d Allan Memorial Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPHENAZINE DECANOATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENYTOIN; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SIMVASTATIN; THIORIDAZINE; ZIPRASIDONE;

ACUTE PSYCHOSIS; ATAXIA; BLURRED VISION; CARDIOVASCULAR RISK; CONSTIPATION; DIABETES MELLITUS; DOPAMINE RECEPTOR BLOCKING; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSULIN RESISTANCE; MEMORY DISORDER; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PROLACTIN BLOOD LEVEL; RISK ASSESSMENT; SEIZURE; SEXUAL DYSFUNCTION; SHORT SURVEY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 77950400901     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371005500305     Document Type: Short Survey

References (0)